MKI67 and breast carcinoma: Subgroup analyses of recurrence and breast cancer mortality by age, tumour size, nodal status, ER and PR status, HER2 status, grade, tumour proliferation (Ki-67), and histological type showed similar proportional risk reductions with no significant heterogeneity (figure 5; appendix pp 16–21).